Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma

Chinese Medical Journal

Volumn 123, Issue 22, 2010, Pages 3206-3211

  Yang, Xi Gui ^a   Jiang, Chao ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Drug resistance; Ligustrazine; Lymphoma; Multiple; Non hodgkin; Toxicity; Treatment efficacy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; METHOTREXATE; PREDNISONE; TETRAHYDROFOLIC ACID; TETRAMETHYLPYRAZINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FEVER; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR REGRESSION;

ADULT; AGED; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PYRAZINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251523174     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.22.006     Document Type: Article

References (20)

1. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145-3167.
2. Li L, Su LP, Ma L, Zhao J, Zhu L, Zhou YA. Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma. Chin J Oncol (Chin) 2009; 31: 199-202.
3. Yang X, Jia L, Wei L, Zuo W, Song S. Correlation of expression levels of multidrug resistance gene 1 (mdr1) mRNA, multidrug resistance associated protein (MRP), and P-glycoprotein (P-gp) with chemotherapy efficacy in malignant lymphomas. Natl Med J China (Chin) 2002; 82: 1177-1179.
4. Xu YC, Lin YM, Zhang FC. The relationship between abnormal MDR gene expression and chemotherapy response in lymphoid malignancies. Chin J Oncol (Chin) 2006; 28: 353-356.
5. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, et al. Clinical reversal of multidrug resistance. Stem Cells 1996; 14: 56-63.
6. Biscardi M, Teodori E, Caporale R, Budriesi R, Balestri F, Scappini B, et al. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk Res 2006; 30: 1-8.
7. Wang X, Chen X. Study on the effects of tetramethylpyrazine on tumor cells: survey and prospects. Chin J Chin Materi Med (Chin) 2003; 28: 295-298.
8. He L, Liu GQ. Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol Sin 2002; 23: 591-596.
9. Zhou C, Shen P, Cheng Y. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim Biophys Acta 2007; 1770: 1011-1020.
10. Mei Y, Shi YJ, Zuo GQ, Gong JP, Liu CA, Li XH, et al. Study on ligustrazine in reversing multidrug resistance of HepG2/ADM cell in vitro. Chin J Chin Materi Med (Chin) 2004; 29: 970-973.
11. Wang XB, Wang SS, Zhang QF, Liu M, Li HL, Liu Y, et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep 2010; 23: 211-215.
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
13. Hirose M. Biology and modulation of multidrug resistance (MDR) in hematological malignancies. Int J Hematol 2002; 76 Suppl 2: s206-s211.
14. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429.
15. Li B, Zhong MZ, Tang TF, Liu W, Huang J. Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma. Chin J Cancer (Chin) 2007; 26: 851-855.
16. Szczuraszek K, Materna V, Halon A, Mazur G, Wróbel T, Kuliczkowski K, et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non- Hodgkin's lymphomas. Oncol Rep 2009; 22: 1315-1323.
17. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957.
18. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009; 50: 728-735.
19. Gao L, Chen L, Fei X, Qiu HY, Zhou H, Wang JM. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. Chin Med J 2006; 119: 911-918.
20. Akoum R, Brihi E, Saade M, Hanna T, Chahine G. Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther 2007; 3: 143-149.